Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Gets First-Ever GMP Warning Letter

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s GMP warning letter to Mylan cites failure to complete a required content uniformity test for generic Imodium manufactured at Puerto Rico plant.

Advertisement

Related Content

Mylan's Manufacturing Maelstrom: Trans-Atlantic Recalls And Personal Citation By Gottlieb
Mylan’s EpiPen Recall: Another Hit On The Auto-Injector
Mylan’s EpiPen Recall: Adding Insult To An Injured Product
Lipitor Generics: Questions About Mylan's ANDA Weigh Heavily In Court's Dismissal Of Lawsuit Against FDA
Establishment Fees Protect American Manufacturing, Mylan Argues In User Fee Proposal
Legal News In Brief
Amnesteem Cannot Claim “Esteem,” FDA Tells Mylan In Letter On Acne Drug

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073079

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel